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Summary In vivo '9F-NMR spectroscopy has been used to study the pharmacokinetics of the experimental
antifolate drug CB3988 (C2-desamino-C2-methyl-N'0-propargyl-2'trifluoromethyl-5,8-dideazafolic acid) in mice
and rats. NMR results have been compared to those obtained by HPLC and the effect of the inclusion of the
CF3 group evaluated by comparing the pharmacokinetics of CB3988 and ICI 198583 (C2-desamino-C2-methyl-
N'°-propargyl-5,8-dideazafolic acid) in rats. In mice, following the administration of CB3988 (500 mg kg-'
i.v.), drug could be detected in both the upper and the lower abdomen. NMR signal from the upper abdomen
reached maximum intensity 10-40min after administration, declining thereafter with a half life of 28 min.
Signal detected in the lower abdomen reached maximum intensity 60-90 min after treatment. HPLC analyses
indicated that CB3988 was present at appreciable concentrations (about 20-30 mg ml-') in both bile and
urine which is consistent with the signal from the upper and lower abdomen being derived from the gall
bladder and urinary bladder, respectively. Studies in rats also indicated that CB3988 (100 mg kg-' i.v.) rapidly
entered and was cleared from the upper abdomen. Comparison of data from rats with intact and cannulated
bile ducts suggested that '9F-NMR could detect CB3988 undergoing enterohepatic circulation. Furthermore,
comparison of the plasma half life of CB3988 with the half life for the decline of the NMR signal from the
upper abdomen suggested that NMR measurements may reflect the plasma clearance of CB3988. When the
pharmacokinetics of CB3988 and ICI 198583 were compared the only significant difference was in the alpha
phase half life which was 2-fold faster for CB3988. These data demonstrate that CB3988 is cleared rapidly by
both biliary and urinary excretion. This is in contrast to N'°-propargyl-5,8-dideazafolic acid, where delayed
excretion is associated with hepatic and renal toxicities. The ability to study CB3988 pharmacokinetics
non-invasively by '9F-NMR spectroscopy confirms the utility of the technique and, since '9F-NMR can be
applied directly to clinical investigations, it may be possible to obtain similar information in humans.
It is now accepted that pharmacokinetics are an important
determinant of both the activity and toxicity of anticancer
drugs (Newell, 1989). This acceptance has led to the inclusion
of pharmacokinetic studies in both the preclinical and early
clinical evaluation of the majority of novel antitumour agents
with two broad aims in mind. Firstly, the studies may be of
direct clinical relevance in determining dose escalation during
phase I studies (Collins et al., 1986; EORTC PAM Group,
1987) and secondly the information gained may be of value
in interpreting both the toxicity and activity of the com-
pound. This latter information can in turn be used to develop
either new drugs or drug schedules which maximise the
therapeutic potential of the agent.
In order to conduct pharmacokinetic studies it is necessary
to have a method which can accurately and selectively
measure levels of the drug and its metabolites in biological
fluids and tissues. Ideally the method should allow studies on
drug levels in tumour deposits and in sensitive normal tissues
since these are more likely to correlate with activity and
toxicity than are levels in plasma or urine. In the preclinical
setting such measurements are usually performed using radio-
chemicals and either autoradiographic or quantitative tissue
distribution studies (Siddik & Newell, 1988). However, in
patients ethical and clinical considerations restrict the use of
radioactive tracers and routine sampling of tumour or nor-
mal tissue is not practicable. Hence, in the majority of studies
in patients, pharmacokinetic data are derived from the study
of readily accessible body fluids, i.e. blood, urine and
occasionally bile and CSF. Using physiological pharmaco-
kinetic modelling it is possible to extract some tissue distribu-
tion information from such data although there is always
considerable uncertainty attached to the results because of
interpatient variation. Thus there is no substitute for direct
drug analysis in the tissue of interest.
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Stevens et al. (1984) were the first authors to demonstrate
the utility of '9F-NMR as a method of non-invasively investi-
gating the pharmacokinetics of a drug in vivo. These authors
were able to measure drug in both the liver and tumours of
mice following the administration of 5-fluorouracil (5FU)
and were also able to detect metabolites of 5FU in both
tissues. These studies have subsequently been extended to
clinical investigations with 5FU (Wolf et al., 1987) and to
work with other fluorinated drugs, most notably the inhala-
tional anesthetics (Wrywicz et al., 1987; Selinsky et al., 1987,
1988a, b).
In the present study the experimental antifolate C2-
desamino-C2-methyl-N'0-propargyl-2'-trifluoromethyl-5,8-dide-
azafolic acid (CB3988, Figure la) has been studied. CB3988
is the 2'trifluoromethyl derivative of C2-desamino-C2-methyl-
N'°-propargyl-5,8-dideazafolic acid (ICI 198583, CB3819,
Figure lb) which is itself an analogue of N'°-propargyl-5,8-
dideazafolic acid (CB3717, Figure lc). Although CB3717
displayed clinical activity it was withdrawn from use because
of a number of side effects which included renal and hepatic
toxicities (Calvert et al., 1986). In experimental systems
ICI 198583 is devoid of acute liver and kidney toxicity
(Newell et al., 1988) and is, surprisingly, markedly more
potent than CB3717 in cytotoxicity studies (Hughes et al.,
1988; Jackman et al., 1988). The lack of toxicity seen with
ICI 198583 is probably a reflection of its greatly enhanced
aqueous solubility compared to CB3717 which is due to the
lack of the 2-NH2 group in ICI 198583. In the case of
CB3717, the presence of two hydrogen bond donors (N3H
and 2-NH2) and two hydrogen bond acceptors (4-0 and N')
allows strong intermolecular interactions and hence poor
solubility. These interactions are reduced in the case of
ICI 198583 which has a 2-methyl group instead of the 2-
amino.
With CB3717 there is a clear relationship between the
pharmacokinetics of the drug and its toxicities. Thus in both
mice and patients the drug is nephrotoxic and this is
associated with its accumulation and retention in the kidney
(Alison et al., 1985; Newell et al., 1986). In mice the drug is
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Cheshire. All other chemicals were of analytical grade where
available and obtained from standard suppliers.
Synthesis ofCB3988
The synthesis of CB3988 (Hughes, 1986; Marsham et al.,
1990) was achieved as outlined in Figure 2. Diazotization of
the nitro aniline (1) and subsequent displacement of the diazo
group by cyanide anion give the nitrile (2). Hydrolysis of the
nitrile to carboxylate (4) was problematic, but was eventually
achieved in two steps via the amide (3). Diethyl glutamate
was condensed efficiently with the carboxylate acid chloride
to give the nitro glutamate (5), which was then hydrogenated
and the resulting amine (6) propargylated to give (7). Propar-
gylamine (7) was coupled to bromomethyl quinazoline (8)
and the coupled diester (9) hydrolysed to give CB3988 in
good overall yield.
In vivo '9F-NMR spectroscopy
Studies in mice '9F-NMR spectra were obtained using an
Oxford Research Systems TMR-32 spectrometer with a 1.9T
horizontal bore magnet. Mice were anaesthetised with 60 mg
kg-' pentobarbitone intraperitoneally (i.p.) and when anaes-
thetised the urethra was ligated externally to prevent urina-
tion. The tail of the animal was warmed (42°C) and CB3988
given intravenously (i.v.) into a tail vein at 500 mg kg-'
(50mg ml-' in 0.15 M NaHCO3, final pH adjusted to 9-9.5
with NaOH). Mice were then placed on a flask pumped with
warm water so as to maintain the body temperature of the
mouse at 36-38°C. The mouse and flask were then placed in
the bore of the magnet and a 14 mm diameter two-turn
(c) CB 3717
Figure I The structures of CB3988 (a), ICI 198583 (b), and
CB3717 (c).
hepatotoxic and this is also associated with CB3717 retention
in the liver (Newell et al., 1986). In contrast, in mice, the
non-toxic ICI 198583 is not retained in either the liver or the
kidney (Newell et al., 1988).
The aim of the present study was to confirm the rapid
clearance of ICI 198583 from the liver and kidney by using
'9F-NMR spectroscopy and in so doing to evaluate the
potential NMR as a non-invasive method for pharmaco-
kinetic monitoring. To achieve this aim the 2'triflouromethyl
derivative of ICI 198583 was synthesised and the clearance of
the drug from the liver and the appearance of the drug in the
urinary bladder determined in mice. In addition, a study was
performed in both normal and bile duct cannulated rats to
determine the contribution ofenterohepatic circulation to the
NMR signal derived from the upper abdomen of the rat. The
results obtained in mice by NMR were compared to those
obtained using high performance liquid chromatography
(HPLC) and in the rat the results obtained with CB3988 were
compared to those gained with ICI 198583 to exclude the
possibility that the present of the 2'trifluoromethyl was mark-
edly influencing the pharmacokinetics of the drug. Certain
aspects of this study have been reported previously in ab-
stract form (Newell et al., 1988).
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Materials
Male C57BL x DBA2 Fl hybrid mice (25-30 g) and female
Wistar rats (180-220 g) were supplied by the National In-
stitute of Medical Research, Mill Hill, London. CB3988 was
synthesised as described below and ICI 198583 was a
generous gift from ICI Pharmaceuticals plc, Macclesfield,
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Figure 2 Route for the synthesis of CB3988.
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surface coil placed over the upper or lower abdomen to
detect signal originating in the liver and urinary bladder,
respectively. NMR data were obtained using a 12 ls pulse
and a 1 s pulse repetition interval. A pulse width of 12 ts was
found to give maximum signal intensity from a fluorine-
containing spherical phantom of 1 cm diameter, placed
immediately under the surface coil. The 900 pulse at the coil
centre was 5yts. Data were collected in 4-8 min blocks for
up to 2 h. Data processing involved exponential multiplica-
tion of the free induction decay equivalent to 40 Hz line
broadening. Additional anaesthetic was given as required
(15 mg kg-' i.p.) without moving the animal.
Studies in rats Rats were anaesthetised with 60 mg kg-'
pentobarbitone i.p. and the trachea, left carotid artery and
left femoral vein cannulated with polyethylene tubing. The
patency of the carotid and femoral cannulae was maintained
throughout the experiment with 10 i.u. ml-' heparin in saline.
The urethra was ligated externally to prevent urination dur-
ing the experiment. In experiments where the effect of inter-
rupting the enterohepatic cycle of CB3988 were conducted
the common bile duct was also cannulated. Once surgery was
complete the rat was placed on a flask pumped with warm
water and the body temperature allowed to equilibrate at
36-38°C. The rat and flask were then placed in the bore of
the magnet and pretreatment samples of blood collected from
the carotid artery and, when cannulated, from the bile duct.
NMR spectra were recorded by placing the surface coil over
the upper abdomen of the rat and, after a pretreatment
spectrum was recorded, CB3988 was given at 100 mg kg-' as
an i.v. bolus dose via the femoral vein (50 mg ml-' in 0.15 M
NaHCO3, pH 9-9.5 with NaOH). Spectra were recorded as
described for mice with the exception that a pulse width of
14 js was employed. Data were collected for up to 60min
with additional anaesthetic being given i.v. as required at
15 ml kg-'. During the course of the experiment a cumulative
bile sample was collected and blood samples (200psl) taken 5,
10, 15, 20, 25, 30, 45 and 60 min after CB3988 administra-
tion. Plasma was prepared by centrifugation. At the end of
the experiment the rats were killed with an overdose of
anaesthetic and the contents of the bladder removed. All
samples were weighed wet and stored at - 20°C prior to
analysis by HPLC. In both mice and rats the doses of
CB3988 used produced no acute toxicity.
Determination ofCB3988 concentrations by HPLC
Mouse samples In a separate series of experiments (Maxwell
et al., 1990) CB3988 was administered to pentobarbitone-
anaesthetised mice as described above. Thirty and 60min
after administration the mice were killed and the liver, small
intestine, large intestine, kidneys, lung, heart, spleen and
stomach removed. The gall bladder was separated from the
liver and the contents of the urinary bladder were removed.
All samples were weighed and then stored at -20°C until
analysed. For HPLC analysis, samples were homogenised in
a teflon/glass homogeniser in 9 volumes of 0.1 M Tris-HCI
pH 10 buffer and urine and bile diluted in the same buffer to
give CB3988 concentrations in the range 0.1-5.0mgml-'.
Aliquots of 0.5 ml of the diluted urine, bile and tissue
homogenates were treated with 1 ml methanol and any resul-
tant precipitate removed by centrifugation for 15min at
1,500 g at 4°C. Aliquots (25 sl) of the resultant supernatants
were analysed using a Waters Associates chromatograph
(Millipore, Harrow, UK) fitted with a 5 gm 15 x 0.46 cm
Spherisorb C6 column (Phase Sep, Queensferry, Clwyd, UK)
and a 5 x 2.1 cm CO:Pell ODS precolumn (Whatman, Clif-
ton, NJ, USA). The column was eluted isocratically with
40:60 methanol:0.18 M acetic acid (v:v) at a flow rate of
1.5 ml min-'. CB3988 was detected by UV absorbence at
280 nm and 313 nm and concentrations were calculated by
external standardisation by comparison of peak areas to
those of 0.1 mg ml-' CB3988 standards dissolved in 0.15 M
NaCO3 and analysed every eight samples. The CB3988 peak
was identified by the 313/280 nm wavelength ratio and by
co-chromatography with authentic CB3988. Results were
expressed both as the absolute concentration (mg g' tissue
wet weight or mg ml-' fluid) and as a percentage of the dose
administered.
Rat samples Samples of rat plasma, urine and bile were
analysed as described above with the exception that 100 gsl of
plasma were analysed by mixing the 200 1 of methanol. A
standard curve for the analysis of CB3988 in rat plasma was
prepared over the concentration range 5-1000#AM CB3988
and over this range the recovery of CB3988 was complete
(98 ± 4%, mean ± s.d., n = 21) and linear (r = 1.000) with
intra and interassay coefficients of variation of < 10%.
Comparison ofthe pharmacokinetics ofCB3988 and
ICI 198583 in rats
To determine any possible effect of the 2'trifluoromethyl
group in CB3988 the pharmacokinetics of ICI 198583 were
also determined in bile duct cannulated rats using the method
described above. The only exception was that the body
temperature of the rats was maintained by using external
heating lamps. ICI 198583 levels were determined in an iden-
tical manner to that described for CB3988. Recovery of
ICI 198583 from rat plasma was also complete (101.9 +
7.4%) and linear (r = 1.000) and under the HPLC conditions
used ICI 198583 (retention volume 11.6 ml) was resolved
from CB3988 (retention volume 16.8 ml) with the 313/280 nm
absorbence ratios also being different (ICI 198583 = 0.94 +
0.08, CB3988 = 0.43 ± 0.01).
Pharmacokinetic analysis ofdata
NMR signals The NMR peak heights for each animal were
measured and then each peak expressed as a fraction of the
most intense peak observed for the individual animal. The
relative peak heights will be proportional to peak areas and
hence to the concentration of free drug in each animal pro-
vided that no changes in line width occur during the course
of the experiment. No such changes were apparent. Peak
intensity vs time plots were then drawn and half-life values
calculated for the decline in peak intensity during the
exponential phase. Half-lives were calculated by non-linear
least squares regression analysis (Jennrich & Sampson, 1968)
using a weighting function of l/(y +9)2.
Plasma levels of CB3988 and ICI 198583 in rats A biexpon-
ential equation was fitted to plasma CB3988 and ICI 198583
levels following their administration to rats. As above, non-
linear least squares regression analysis employing a weighting
function of l/(y + 9)2 was used. From the fitted equation the
alpha and beta phase half-lives, clearance and volume of
distribution at steady state were calculated using standard
equations (Houston, 1985).
Results
'9F-NMR spectroscopy ofCB3988 in mice
Figure 3 shows examples of the spectra obtained from the
upper abdomen of mice 40, 80 and 120 min after the i.v.
administration of 500 mg kg-' CB3988. These data show that
the NMR signal was readily detectable at these time points;
however, the signal was nearing the limit of detection at
120 min. No clear evidence of the presence of additional
peaks in the NMR spectrum was seen at any time point and
hence metabolism of CB3988 at a site close enough to the 2'
position to substantially alter the chemical shift of the tri-
fluoromethyl signal is not indicated. Figure 4 displays the
time course for the appearance and disappearance of the
signal in the upper abdomen of mice and shows that the
signal tended to increase over the first 10-40min, decaying
therafter. The half-lives for the decline in the NMR signal for
the three mice whose data are given in Figure 4 were 23 ± 4,'9F-NMR SPECTROSCOPY OF A QUINAZOLINE ANTIFOLATE 769
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Figure 3 NMR spectra from the upper abdomen of a mouse 40,
80 and 120 min after the administration of 500 mg kg-' i.v.
CB3988. Chemical shift in PPM are expressed relative to a 5-
fluorouracil external standard.
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Figure 4 Time course for the appearance and decline of NMR
signal in the upper abdomen of mice following 500 mg kg- i.v.
CB3988. Each line represents data from an individual mouse.
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In order to allow the NMR signals arising from the upper
and lower abdomen of the mice to be ascribed to particular
organs of the mouse a conventional quantitative tissue distri-
bution study was performed 30 and 60 min after administra-
tion. As shown in Table I, of the organs analysed only the
gall bladder and urinary bladder contained drug at appre-
ciable concentrations (about 20-30mgml'). Of the other
organs studied only the liver and small intestines contained
drug in excess of 1 mg g-' wet weight. On the basis of these
data it seems probable that the signal arising from the upper
abdomen is derived primarily from drug in the gall bladder
whilst signal from the lower abdomen corresponds to drug in
the urinary bladder.
Table I CB3988 concentrations in mouse tissues 30 and 60 min after
the administration of 500 mg kg-' i.v.
30min 60min
Tissue Conc. %Dose Conc. %Dose
Urine 25± 12 18±1 26±4 31±4
Bile 26± 15 1.3±1.2 23±4 1.3±0.6
Liver 1.3±0.1 17±2 1.6±0.2 15±2
Small 1.3±0.9 13±8 2.6±0.4 28±8
intestine
Kidney 0.8±0.8 2.3±2.4 0.6±0.7 1.8±2.2
Large 0.07±0.02 0.42± 0.23 ND ND
intestine
Lung 0.18±0.09 0.29±0.18 0.10±0.09 0.13±0.12
Heart 0.10± 0.04 0.13±0.05 0.05± 0.03 0.02± 0.02
Spleen 0.05±0.01 0.03±0.01 0.03±0.03 0.02±0.02
Stomach 0.10±0.08 0.30± 0.25 0.06±0.02 0.23± 0.09
Concentrations are mgCB3988 per ml urine or bile and per g wet
weightforthetissuesanalysed. %Doseisthe % ofthedoseadministered
present in the total sample. ND, <0.02 mg g 'wet weight. Values are
the mean±standard deviation of data from 3-4 mice.
'9F-NMR spectroscopy ofCB3988 in rats
The time course for the appearance and decline of NMR
signal from the upper abdomen of rats following the
administration of 100 mg kg' CB3988 is shown in Figure 6.
Data for rats with intact and cannulated bile ducts are given
and, as in the case of mice, all spectra contained only the
peak associated with CB3988, no metabolites being detected.
In both cannulated and bile duct-intact rats, NMR signal
was detected within 2 min of the bolus dose of CB3988 with
signal intensity reaching a maximum value by 10 min. There-
after the signal declined rapidly, particularly in bile duct
cannulated rats where the limit of detection was reached by
15-20 min and signal was not detected again during the
remainder of the experiment (60 min). The half-lives for the
decline in the NMR in the three bile duct cannulated rats
were 6.5 ± 0.8, 6.9 ± 0.8 and 5.6 + 2.9 min, overall mean
6.5 ± 0.8 min. In the rats with intact bile ducts the NMR
signal did not decline as rapidly as in the cannulated rats and
did not drop below the limit of detection during the experi-
ment (0-60 min). Indeed, in two of the rats, from 30 min
onwards the NMR signal had stabilised. These data suggest
that the signal detected in rats with intact bile ducts is due in
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Figure 6 Time course for the appearance and decline of NMR
signal in the upper abdomen of rats following 100 mg kg-' i.v.
CB3988. Solid lines are rats with bile duct cannulae and broken
lines are animals with intact bile ducts. Each line represents data
from an individual rat.
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Figure 7 Plasma concentrations of CB3988 (0, A) and ICI
198583 (0) in rats following 100mgkg-' i.v. Data for CB3988
are from rats with intact bile ducts (0) and those with can-
nulated bile ducts (A). Points are the mean of estimations in
three rats for each treatment and bars the standard deviations of
the means.
Table II Effect of bile duct cannulation and the 2'trifluoromethyl
group on the pharmacokinetics of CB3988 in the rat (100mg kg-'
i.v.)
Compound CB3988 CB3988 ICI198583
Bile duct cannula - + +
t1/2 alpha (min) 4.1± 1.0 3.3±0.8 6.1±0.9
t1/2 beta (min) 22±4 27± 12 30±8
Vb (ml kg-I)a 105±24 104± 13 128± 15
Vd,,(ml kg I)b 168±25 217±61 229±83
Clearance (ml min-' kg-') 14.2±3.1 15.4±3.0 10.6± 1.6
Excretion (% dose, 0-60 min)
Biliary - 77±7 75±8
Urinary 7.6±0.7 9.7± 1.0 ND
Valuesarethemean±s.d. from threeratsforeachtreatment. ND, the
0-60 minurinaryexcretion forICI 198583 wasnotdetermined, butthe
0-240 min cumulative urinary excretion was 17.3 ±0.6% ofthe dose.
aVi, apparent volume of the central compartment. bVd., apparent
volume of distribution at steady state. cClearance, total plasma
clearance.
part to drug re-entering the liver as part of the enterohepatic
cycle. However, as shown in Figure 7 and Table II, there
were no significant differences in the plasma levels or urinary
excretion of CB3988 in rats with or without bile duct can-
nulae which probably reflects efficient uptake of CB3988
present in the portal system such that there is no passage of
compound into the systemic circulation.
Comparison ofthepharmacokinetics ofCB3988 and
ICI 198583 in rats
To investigate the possibility that the 2'-trifluoromethyl
group of CB3988 was a major determinant of the pharma-
cokinetics of the drug a comparison was made between
CB3988 and its parent ICI 198583. The plasma levels of
CB3988 and ICI 198583 are shown in Figure 7 and the
pharmacokinetic parameters and urinary and bilary excretion
data given in Table II. Inclusion of the 2'-trifluoromethyl
group reduced the alpha phase half-live value (t test,
P = 0.004) and this led to levels of CB3988 being lower than
those of ICI 198583, however, this was the only pharma-
cokinetic parameter for which there was a significant
difference between CB3988 and ICI 198583.
Discussion
The aim of the present study was to evaluate the utility of
non-invasive '9F-NMR spectroscopy as a method of studying
the pharmacokinetics of the antifolate CB3988 in mice and
rats. This study is important both with regard to this partic-
ular class of compounds and because there is a general need
to study non-invasive methods of pharmacokinetic monitor-
ing in cancer chemotherapy. In both mice and rats NMR
signal could be readily detected in the upper abdomen of the
animal shortly after drug administration. Comparison of the
NMR data with those of a conventional quantitative tissue
distribution study performed using HPLC analysis demon-
strated that the signal in the upper abdomen of mice was
most probably derived from the gall bladder. Associated
studies using whole body '9F-NMR imaging in mice follow-
ing the administration of CB3988 confirm that the signal
from the upper abdomen is derived from a discreet volume
whose position is anatomically consistent with that of the
gall bladder (Maxwell et al., 1990). The other area examined
in mice was the lower abdomen where signal was also readily
detected. Again on the basis of HPLC analyses (Table I) and
'9F-NMR imaging (Maxwell et al., 1990) the source of the
signal would appear to be primarily the urinary bladder. The
time course of the appearance of the drug in the bladder
indicates that the urinary excretion of the drug occurs rapidly
and is essentially complete within 1 h (Figure 5). This is in
marked contrast to the nephrotoxin CB3717 where there is
delayed urinary excretion and drug still present in the kidney
weeks after administration (Newell et al., 1986). Thus NMR
does appear to be capable of identifying rapid urinary
elimination with this class of compound. In the light of
clinical experience with CB3717 (Calvert et al., 1986; Alison
et al., 1985) this information would be useful in the early
clinical evaluation of CB3717 analogues.
In addition of urinary excretion, faecal elimination con-
stitutes the other major route of excretion for CB3717
(Newell et al., 1986) and its analogues (Newell et al., 1988).
Faecal elimination is preceded by biliary clearance with the
majority of the dose present in the bile within I h in the case
of both ICI 198583 and CB3988 (Table 11). This is also the
case for CB3717 itself at non-hepatotoxic doses (Newell &
Siddik, unpublished results). Since biliary excretion is the
major route of elimination, and the NMR signal from the
upper abdomen of mice derives from the bile in the gall
bladder, a relationship between the rate of decline in the
plasma levels of CB3988 and the NMR signal might be
anticipated. Although the plasma levels of CB3988 in mice
were not determined as part of the present study, previous
results with other C2-desamino quinazolines indicate that the
plasma half-life is approximately 20 min (Newell et al., 1988).
This value is consistent with that of 28 ± 6 min for the
decline in the NMR signal reported herein. Thus for drugs
which undergo extensive biliary elimination NMR studies of
drug clearance from the liver may offer an indirect measure
of plasma half-life. More generally, in those cases where
drugs can be detected in organs of direct therapeutic or
toxicological interest the results of NMR experiments may be
more relevant than plasma analyses. For example, the rela-
tionship between drug levels in tumour tissue and activity
should be better than that between plasma levels and activity.
Experiments were performed in rats to further investigate
the relationship between CB3988 plasma half-life and the
decline in NMR signal since it was technically possible to
take blood samples, collect bile and perform spectroscopic
experiments on the same animal. The experiments in bile
duct cannulated rats, where enterohepatic circulation cannot
occur, indicated that the alpha phase half-life for the
clearance of CB3988 from plasma was 3.6 ± 0.3 min while
the NMR signal from the upper abdomen decreased with a
half-life of 6.5 ± 0.8 min. The similarity of these values again
encourages the view that the signal from the liver can be used
as an indirect measure of the plasma half-life of a drug,
provided that the liver is the major organ for the clearance of
the compound. When experiments were repeated in rats with
an intact bile duct a more complex profile was obtained for
the time course of NMR signal intensity from the upper
abdomen (Figure 6). The difference between these results and
those in bile duct cannulated animals strongly suggests an
element of enterohepatic circulation in the disposition of the
drug. Enterohepatic circulation has been observed in rats
with CB3717 (Newell & Siddik, unpublished results) and'9F-NMR SPECTROSCOPY OF A QUINAZOLINE ANTIFOLATE 771
methotrexate (Griffin & Said, 1987), and hence is not unex-
pected.
The rapid decline in the NMR signal from the liver of
both mice and rats following CB3988 administration is again
in contrast to the data obtained in mice (Newell et al., 1986)
and rats (Newell & Siddik, unpublished results) with CB3717.
In both species reduced clearance of the drug from the liver
was associated with hepatotoxicity. With C2-desamino ana-
logues of CB3717 both retention of drug in the liver and
hepatotoxicity are absent (Newell et al., 1988). However,
these results were obtained using invasive techniques. The
demonstration in the present study that it is possible to show
rapid hepatic clearance non-invasively by NMR is again an
encouraging result which would also be of value in the early
clinical evaluation of CB3717 analogues.
The final point investigated in this study concerned the
impart of the inclusion of the 2'-trifluoromethyl group on the
pharmacokinetics of the antifolate molecule. In this respect
the only significant effect of the 2'-trifluoromethyl group was
to reduce the alpha phase half-life value with the result that
plasma levels of CB3988 were lower than those of ICI 198583
(Figure 7). No other major qualitative or quantitative altera-
tions in the distribution of the molecule, its clearance or its
routes of elimination were observed.
However, it should be noted that associated biochemical
studies have shown that the presence of the 2'-trifluoromethyl
group reduces both the inhibitory activity of the compound
towards the target enzyme, thymidylate synthase (7-fold),
and the cytotoxicity of the agent (14-fold) in comparison to
ICI 198583 (A.L. Jackman, unpublished results). Thus the
potential problems of including the trifluoromethyl group as
a 'label' in candidate drugs should not be underestimated and
the use of a single fluorine atom may be more appropriate,
but the resultant loss in sensitivity might compromise the
utility of the methodology.
With regard to the general application of '9F-NMR in
pharmacokinetic studies a number of points need to be con-
sidered. The major limitation of NMR is that the technique
has only limited sensitivity. Thus in the present study signal
detected in the upper and lower abdomen of mice was
ascribed to drug present in the bile and urine at concentra-
tions of 20-30mgml1' (40-60mM). The dynamic range in
these studies was approximately 10-fold and hence that limit
of detection would be in the region of 4mM. This figure
could be reduced by the use of longer aquisition periods;
however, in so doing time resolution would be lost which
may be critical in the case of drugs with short half-lives. In
contrast, conventional methods involving radiochemical and/
or chromatographic analyses can provide information on
drug levels in the low nM region. Thus, in the absence of
marked improvements in sensitivity, in vivo '9F-NMR will
only find application in those cases where relatively large
doses of drug can be administered. This was possible in the
case of CB3988 as C2-desamino quinazoline antifolates can
be administered to mice at 500mgkg-' without producing
any acute toxicity (Newell et al., 1988). Since a number of
antitumour agents are relatively impotent compounds, with
clinical doses in the 100 mg to I g range, cancer
chemotherapy represents an ideal area in which to assess the
applications and limitations of in vivo '9F-NMR.
Despite the limitations of sensitivity with regard to in vivo
spectroscopy, it is already clear that ex vivo analytical '9F-
NMR does have considerable potential as a method to study
drug and metabolite levels using biological fluids and isolated
tissues. A number of studies have already shown the utility of
the method in the case of the fluoropyrimidine drugs (Malet-
Martino et al., 1984, 1986; Keniry et al., 1986; Vialaneix et
al., 1987; Hull et al., 1988). The use of 'fluorine labels' in
other anticancer drugs is clearly warranted and recent work
with nitroimidazoles is a further example of this (Maxwell et
al., 1989). The studies with the fluoropyrimidines serve to
highlight the major strength of NMR over radiochemical
studies, namely, that the technique provides separate inform-
ation on drug metabolites and the parent compound and not
just on total drug derived material. This aspect of '9F-NMR
was not apparent from the study reported in the present paper
because quinazoline antifolates do not undergo extensive
metabolism. Thus in the case of CB3717, the only extra-
cellular metabolite which has been detected is the desgluta-
mate compound which was found in the faeces and was
shown to be a product of bacterial metabolism in the gastro-
intestinal tract (Newell et al., 1986). Although polyglutamate
metabolites of CB3717 have also been detected, both in vitro
(Sikora et al., 1988) and in vivo (Manteufel-Cymborowska et
al., 1986; Nair et al., 1986), these compounds are thought to
be rapidly catabolised once outside the cell. Within the cell
polyglutamates are probably highly protein bound and would
not have the freedom of motion required for a molecule to
be detected by NMR. This requirement for molecules to be
free to move in order to be detected by NMR spectroscopy
may place an additional limitation on the detection of drugs
in biological tissues since the line widths of NMR signals
depends upon the rotational freedom of the nuclei involved.
Thus the binding of a small molecule to a protein can result
in line broadening to such an extent that some or all of the
nuclei become 'NMR invisible'. Preliminary studies with
CB3988 indicated that when the drug was added at 2 mM to
a 50% (v/v) mouse liver homogenate the peak height signal
to noise ratio was reduced 4-fold relative to an aqueous
solution of the drug at the same concentration. Further
experiments are required to define the extent to which this
phenomenom will limit the application of in vivo NMR.
In conclusion, this study has demonstrated the utility of in
vivo '9F-NMR spectroscopy as a method for studying the
pharmacokinetics of a quinazoline antifolate drug in mice
and rats. The results obtained by NMR indicate that CB3988
is cleared rapidly by both biliary and urinary elimination.
These data are consistent with the lack of liver and kidney
toxicity found with the C2-desamino CB3717 analogues.
Comparison of the NMR data with data obtained using
conventional HPLC methodology indicates that the NMR
signals detected in the upper and lower abdomen of mice are
derived from the gall bladder and urinary bladder, respec-
tively. Pharmacokinetic analyses in both mice and rats sug-
gest that the rate of decline of the NMR signal derived from
the upper abdomen may reflect the rate of drug clearance
from the plasma and that in rats NMR can detect compound
undergoing enterohepatic circulation. Comparison of the
pharmacokinetics of CB3988 and ICI 198583 in rats indi-
cated that the inclusion of the 2'trifluoromethyl group
reduced the alpha phase half life, however, it did not
markedly alter the rate or route of drug clearance. In view of
the non-hazardous nature of in vivo NMR spectroscopy the
studies reported herein are directly applicable to clinical
investigations with the potential to provide hitherto un-
obtainable information.
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